Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 10,869 matching trials from the live ClinicalTrials.gov search.
Conditions
Bipolar Disorder
Interventions
lamictal
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 17 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
46
States / cities
Dothan, Alabama • Scottsdale, Arizona • San Diego, California + 39 more
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
dim light at night
Other
Lead sponsor
Ulysses Magalang MD
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Overweight, Obesity
Interventions
pramlintide acetate, metreleptin, placebo-P, placebo-M
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
36
States / cities
Birmingham, Alabama • Chandler, Arizona • Santa Rosa, California + 33 more
Conditions
Hepatocellular Carcinoma
Interventions
AZD5851
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 13 more
Conditions
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Interventions
TAS6417, CYP Cocktail, Transporter Cocktail
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Duarte, California • Boston, Massachusetts + 15 more
Conditions
Atrial Fibrillation, Tachycardia, Supraventricular, Arrhythmia, Bradycardia
Interventions
Intervention Pacing Features
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
34
States / cities
Little Rock, Arkansas • Rancho Mirage, California • San Diego, California + 31 more
Conditions
Pancreatic Adenocarcinoma
Interventions
Electronic Health Record Review, Smartphone Application-based Intervention, Survey Administration
Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Myelofibrosis
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
27
States / cities
Little Rock, Arkansas • Berkeley, California • Orange, California + 23 more
Conditions
Breast Cancer Female, Breast Cancer, Male, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Residual Disease, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma
Interventions
DC1 Vaccine, WOKVAC Vaccine
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Indianapolis, Indiana + 4 more
Conditions
Vulvar Lichen Sclerosus
Interventions
Fractionated CO2-laser, Clobetasol Propionate 0.05% Ointment
Device · Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
San Diego, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Terminated Phase 4 Interventional Results available

Prophylactic Phenobarbital After Neonatal Seizures

NCT01089504
Conditions
Neonatal Seizures
Interventions
phenobarbital, placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
2 Days to 2 Weeks
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
18
States / cities
Little Rock, Arkansas • San Francisco, California • Iowa City, Iowa + 12 more
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Secondary Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Secondary Acute Myeloid Leukemia
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Punch Biopsy, Questionnaire Administration, Ruxolitinib, Venetoclax
Drug · Procedure · Other
Lead sponsor
Jennifer Saultz
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Columbus, Ohio • Portland, Oregon • Dallas, Texas
Conditions
Gastrointestinal Stromal Tumors
Interventions
CGT9486, Pexidartinib, Sunitinib
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
6
States / cities
Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Active, not recruiting Not applicable Interventional Results available

Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial

NCT02000115
Conditions
Aortic Valve Stenosis
Interventions
Portico transcatheter aortic valve, Commercially available transcatheter aortic valve
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
21 Years and older
Enrollment
1,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Concord, California + 56 more
Conditions
Cardiovascular Diseases, Statin Adverse Reaction
Interventions
Bempedoic acid 180 mg tablet, Matching placebo tablet
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
13,970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
304
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 246 more
Conditions
Kidney Cancer, Renal Cell Carcinoma
Interventions
Cabozantinib, Nivolumab, Cytoreductive nephrectomy
Drug · Procedure
Lead sponsor
Mark Stein
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
4
States / cities
New Brunswick, New Jersey • New York, New York • Cleveland, Ohio + 1 more
Conditions
Immunoglobulin A Nephropathy, Glomerular Disease, IgAN
Interventions
Dose-Placebo, Low Dose-VIS649, Medium Dose-VIS649, High Dose-VIS649
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • Oxnard, California + 13 more
Conditions
Parenting, Problem Behavior, Premature Birth, Parenting Intervention
Interventions
ezParent, Coaching calls, Active Control
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
20 Months and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Columbus, Ohio
Conditions
Diabetes Mellitus
Interventions
Insulin Lispro, Exubera
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
62
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more
Conditions
Hypertension, Pulmonary
Interventions
Tadalafil, Placebo, ERA as specific PAH treatment
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
7
States / cities
Atlanta, Georgia • Detroit, Michigan • Cincinnati, Ohio + 4 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
afatinib, erlotinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
33
States / cities
Chandler, Arizona • La Jolla, California • Sacramento, California + 27 more
Recruiting No phase listed Observational

Follow-up Visit of High Risk Infants

NCT00009633
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Interventions
No Intervention
Other
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
18 Months to 26 Months
Enrollment
68,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2030
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 26 more
Conditions
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma
Interventions
Akt Inhibitor MK2206, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
22
States / cities
Beverly Hills, California • Duarte, California • Los Angeles, California + 18 more
Conditions
Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
Interventions
LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
17
States / cities
Santa Monica, California • Aurora, Colorado • Denver, Colorado + 10 more